Tysabri® | Natalizumab | Biogen/Elan
10 Sep 2020 | All | All | Neurology Advisor reports a new study indicates that natalizumab may be more effective than fingolimod or BRACETD in reducing relapses in patients with relapsing-remitting multiple sclerosis.
21 Nov 2019 | All | Polpharma/Sandoz | Polpharma commences dosing in Phase III trials of proposed natalizumab biosimilar.
12 Oct 2019 | All | Polpharma/Sandoz | Polpharma publishes details of upcoming phase III clinical trials of biosimilar natalizumab candidate. The study will involve approximately 260 patients with relapsing-remitting multiple sclerosis.
03 Sep 2019 | All | Pfizer & Polpharma Biologics | Pfizer and Polpharma announce licensing deal for natalizumab biosimilar. Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.